IN8BIO, INC. leverages its proprietary DeltEx gamma-delta T cell platform to develop multiple cell therapy candidates targeting cancer and autoimmune diseases, with early clinical data suggesting promising efficacy signals. Despite progress in clinical trials, the company continues to operate at significant losses, though operating income improved by over 36% in FY2025 versus prior years. Liquidity remains a key concern with a high current ratio counterbalanced by going concern disclosures and dependency on third-party manufacturing. Regulatory and commercial hurdles compound operational risks in this complex biotech space. Key milestones to watch include advanced clinical trial readouts and successful scale-up of bio-manufacturing.